Thelansis

  Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality, accounting for up to 4% of cancer-related deaths worldwide. Of concern, despite treatment, the mortality rates remain high and essentially unchanged over the last two decades. Furthermore, even in adjuvant therapy, 5-year survival rates remain poor at only 25%, while for metastatic disease, it is 1%. Such poor statistics are undoubtedly compounded by the fact that current backbones to treatment, fluorouracil or gemcitabine, have remained unchanged over the last 10-20 years and continue to form the basis for new combinations approaches. Consequently, there is an ongoing need for the development of improved diagnostic techniques, treatment options, and surveillance markers to enhance the outcomes of this devastating disease.   Pancreaticoduodenectomy is the most common surgery for pancreatic head carcinomas. Incidence of benign disease at pancreatiduodenectomy ranges from approximate...